Clik here to view.
Debate: Intralesional systemic therapy useful in unresected, regionally...
NEW YORK – Merrick I. Ross, MD, discusses his academic debate with Jeffrey S. Weber, MD, PhD, regarding the current role of systemic intralesional therapies. Ross illustrates that patients with...
View ArticleClik here to view.
Therapy with vismodegib effective in locally advanced, metastatic basal cell...
NEW YORK — In this video, Rogerio I. Neves, MD, PhD, FACS, presents data from a single-center study in which the hedgehog inhibitor, vismodegib, demonstrated encouraging activity in patients with...
View ArticleClik here to view.
Review highlights immunotherapy of advanced melanoma with immune checkpoint...
NEW YORK – Steven J. O’Day, MD, reviews the current role of immune checkpoint inhibitors, such as ipilimumab as well as monoclonal antibodies targeting the PD-1 protein or its ligand, PD-L1, in the...
View ArticleClik here to view.
MSLT-1: Sentinel-node biopsy improved DFS, staging in melanoma
NEW YORK — In this video, Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, discusses final results of the MSLT-1 trial which indicated that sentinel lymph node biopsy after wide excision improved DFS...
View ArticleClik here to view.
Trial updates on injectable oncolytic immunotherapy for metastatic melanoma
NEW YORK — Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, highlights the contrasting results from the two completed phase 3 trials involving velimogene aliplasmid and talimogene laherparepvec. Andtbacka...
View ArticleClik here to view.
Age, preoperative size predicted subclinical spread of melanoma in situ...
NEW YORK — In this video, Tuzar M. Shin, MD, PhD, presented data which indicated that a patient’s age and the preoperative size of lesions may help predict subclinical spread of melanoma in situ...
View ArticleClik here to view.
Review highlights changes in the diagnosis, management of desmoplastic melanoma
NEW YORK – Merrick I. Ross, MD, discusses recent studies which highlighted possible treatment changes for desmoplastic melanoma, a relatively rare variant of malignant melanoma that exhibits distinct...
View ArticleClik here to view.
Review highlights advances in immune checkpoint blockade, novel antibody targets
NEW YORK – Jason J. Luke, MD, FACP, discusses paradigm changing developments in immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with ipilimumab, and targeting of BRAF V600,...
View ArticleClik here to view.
Highlights from the 2014 HemOnc Today Melanoma and Cutaneous Malignancies...
NEW YORK — Sanjiv S. Agarwala, MD, highlights the topics covered at the HemOnc Today Melanoma and Cutaneous Malignancies meeting including surgical treatments, therapy, metastatic disease and even...
View ArticleClik here to view.
Ipilimumab may become standard of care for adjuvant melanoma therapy
Lynn M. Schuchter, MD, chief of the division of hematology/oncology at Abramson Cancer Center at the University of Pennsylvania, explores the provocative question of whether ipilimumab may replace...
View ArticleClik here to view.
Trials yielded conflicting results for injectable intralesional therapies
Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, associate professor of surgery at Huntsman Cancer Institute at the University of Utah, discusses the opposing results observed in two phase 3 trials of...
View ArticleClik here to view.
Review highlights clinical efficacy, toxicity of BRAF inhibitors
Grant McArthur, MB, BS, PhD, offers a refresher course in what is currently known on signaling of the BRAF/MEK pathway, highlighting data that point to the efficacy of inhibiting this pathway in...
View ArticleClik here to view.
Presentation highlights advances in metastatic melanoma treatment
In his presentation, Antoni Ribas, MD, PhD, offers a review of BRAF inhibitor combinations for the treatment of melanoma, and discusses the mechanisms of resistance and how researchers are working to...
View ArticleClik here to view.
TruInject system aims to train on injections
TruInject wrote: TruInject provides injectors with an advanced platform for top tier training and certification. Designed with patient safety in mind, TruInject is the first patent pending training...
View ArticleClik here to view.
